Galderma Launches Alastin ® in China, Supporting the Skin’s Natural Regenerative Abilities in a Rapidly Expanding Market
Galderma (SIX: GALD) today announced the launch of four core Alastin® products in China, marking the premium medical skincare brand’s debut in one of the world’s fastest growing aesthetic skincare markets.6-8 This is the first launch to feature Alastin by Galderma’s new re-energized, premium look and feel, a bold evolution that reflects its leadership in perioperative skincare.
Alastin offers full-spectrum care for patients undergoing aesthetic procedures, from pre-treatment preparation to post-treatment recovery and at-home maintenance, supporting the skin’s natural regenerative abilities to improve overall skincare results.1,2,9-13 With over 50 global dermatological publications and 22 patents, Alastin is strongly backed by science and is the number one peri-procedural skincare brand in the United States.14-16 This launch follows the strong growth of Alastin in other key markets and demonstrates Galderma’s commitment to addressing the needs of patients with science-backed solutions.
“With Alastin by Galderma, we have a comprehensive perioperative solution to enhance skin recovery around aesthetic treatment and maintenance programs that bring together Galderma’s leading expertise in Dermatological Skincare and Injectable Aesthetics. As the Asia-Pacific region’s beauty and aesthetics market continues to grow at pace, we’re proud to bring Alastin to patients in China who are seeking advanced solutions to support them in their aesthetic journeys.”
|
Comprehensive perioperative solutions addressing growing needs
Four core Alastin products that cover all stages of the aesthetic treatment process will now be available in China, creating an integrated in-clinic and at-home skincare program:
- Regenerating Skin Nectar to optimize visible treatment results9
- HA (Hyaluronic Acid) IMMERSE Serum™ to hydrate and support skin barrier repair10
- INhance Serum helps to enable quicker recovery after treatment with injectables, improving the appearance of the skin post-injection11
- Restorative Skin Complex to support aesthetic treatment results by helping to reduce the visible signs of aging12
This comprehensive perioperative series of regenerative skincare products advances aesthetic treatments from isolated procedures to full-spectrum management.1,2,9-12 It reflects Galderma’s holistic approach to aesthetic care – working across its Dermatological Skincare and Injectable Aesthetics portfolios to ensure that products complement each other, delivering seamless, science-backed solutions that elevate patient outcomes.1,2,9-13 Select products are powered by proprietary TriHex Technology® to further enhance skin regeneration and recovery.1,2,13
China’s medical aesthetics market is experiencing remarkable growth, and is projected to increase by up to 15% in the next decade.17 As aesthetic treatments become increasingly mainstream there is rising demand for perioperative skincare, with consumers willing to invest in advanced technologies and premium products to achieve optimal aesthetic outcomes.3-6,17 With its proven efficacy and full-spectrum approach to pre- and post-procedure care, as well as at-home maintenance, Alastin by Galderma is uniquely positioned to address this need.1,2,6-9
“We’re seeing an incredible rise in demand for aesthetic procedures in China, and with that comes a growing need for effective perioperative skincare. Alastin by Galderma brings a scientifically advanced approach to skin recovery, and I’m excited to see Chinese patients gain access to products that can truly support their skin before and after treatment, and elevate their overall results.”
|
This launch marks ten years of pioneering innovation with Alastin, demonstrating Galderma’s commitment to purposeful growth with the brand’s refreshed premium look and feel, and entry into one of the fastest growing aesthetic skincare markets. Following strong growth in North America, Latin America, Australia, and the U.K. & Ireland, Alastin is now undergoing rapid international expansion, offering its premium products to even more patients. By identifying emerging patient needs and delivering science-backed solutions, Galderma continues to shape the future of dermatology and elevate outcomes across the aesthetic journey.
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
References | |
1. | Widgerow AD, et al. Extracellular Matrix Modulation: Optimizing Skin Care and Rejuvenation Procedures. J Drugs Dermaol. 2016;15(Suppl 4):s63–71. |
2. | Widgerow AD, et al. Preoperative Skin Conditioning: Extracellular Matrix Clearance and Skin Bed Preparation, A New Paradigm. Aesthetic Surgery Journal 2019;39(Suppl 3):s103–11. doi:10.1093/asj/sjz022 |
3. | Guidepoint Qsight. From Gen Z to GLP-1s: Trends Reshaping the Medical Aesthetics Industry. Accessed September 2025. Available online. |
4. | Verified Market Reports. Preoperative Skin Preparation Market. Accessed September 2025. Available online. |
5. | PW Consulting Health Care Research Center. Post Procedure Skin Care Product Market. Accessed September 2025. Available online. |
6. | Kwon SH, et al. Experiences and attitudes toward aesthetic procedures in East Asia: a cross-sectional survey of five geographical regions. Arch Plast Surg. 2021;48(6):660-669. doi: 10.5999/aps.2020.02565. |
7. | Fortune Business Insights. China Skincare Market Size, Share & Industry Analysis. Accessed September 2025. Available online. |
8. | Mordor Intelligence. China Cosmetic Products Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030). Accessed September 2025. Available online. |
9. | Alastin. Regenerating Skin Nectar with TriHex Technology®. Accessed September 2025. Available online. |
10. | Alastin. HA (Hyaluronic Acid) IMMERSE Serum™. Accessed September 2025. Available online. |
11. | Alastin. INhance Post-Injection Serum with TriHex Technology®. Accessed September 2025. Available online. |
12. | Alastin. Restorative Skin Complex with TriHex Technology®. Accessed September 2025. Available online. |
13. | Lee WW, et al. A Multi-Center Evaluation of Restorative Eye Treatment and INhance With Trihex Technology to Improve Aesthetic Outcomes When Used Pre- and Post-Blepharoplasty. Aesthet Surg J Open Forum. 2022 Dec 14;5:ojac089. doi: 10.1093/asjof/ojac089. |
14. | Galderma. Data on File. Alastin Publication List. |
15. | Galderma. Data on File. Alastin Patent List. |
16. | Galderma. Data on File. LifeSci Consulting Primary Market Research. 2022. |
17. | Chameleon Pharma. China’s Dynamic Aesthetic Medicine Market: Outlook, Trends, and Opportunities. Accessed September 2025. Available online. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250909403223/en/
Contacts
For further information:
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62
Céline Buguet
Franchises and R&D Communications Director
celine.buguet@galderma.com
+41 76 249 90 87
Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12
Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press Release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press Release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
Civil Air Patrol Expands Fleet With 15 New Cessna Aircraft to Support Lifesaving and Community Missions15.12.2025 17:00:00 CET | Press Release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, announced today that Civil Air Patrol (CAP), the world’s largest operator of Cessna aircraft, is strengthening its national mission capabilities with an order for 15 additional piston-engine aircraft, including seven Cessna Skyhawk 172 and eight Cessna Skylane 182 models scheduled for delivery throughout 2026. The order follows recent deliveries of an additional two Cessna Skylane and one Cessna Turbo Stationair HD aircraft, expanding CAP’s fleet to more than 500 Cessna aircraft nationwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215613573/en/ Delivery of an additional two Cessna Skylane and one Cessna Turbo Stationair HD aircraft joins CAP’s fleet of more than 500 Cessna aircraft nationwide. Cessna aircraft are designed and produced by Textron Aviation. “Civil Air Patrol’s missions demand aircraft that are reliable, versatile and ready to perform in critic
Winston & Strawn and Taylor Wessing UK to Combine, Creating a Premier Transatlantic Law Firm15.12.2025 16:52:00 CET | Press Release
Winston & Strawn and Taylor Wessing’s UK-led business announced today their intention to combine, creating a premier transatlantic law firm that would operate under a new shared name, Winston Taylor. The combination responds to increasing client demand for seamlessly integrated US–UK–EU counsel for the businesses, people, and markets driving capital and innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215914957/en/ The combination once final will unite two international firms with more than 400 years of combined history, complementary strengths, and a common vision to meet clients’ evolving global needs. The combined firm will include more than 1,400 lawyers, establishing one of the largest transatlantic firms whose footprint is primarily in the United States, the United Kingdom, and Europe, and also in Latin America and the Middle East. Leveraging significant strength and scale in major litigation, critical tra
Despite Barriers, Financial Institutions are Clear About AI's Greatest Impact15.12.2025 16:32:00 CET | Press Release
HTEC, a global AI-first provider of software and hardware design and engineering services, today released The State of AI in Financial Services & Insurance 2025, a first industry subset of its global research report in AI. This publication offers one of the clearest views to date into how financial institutions are adopting and scaling artificial intelligence. This industry-focused report analyzes insights from 250 C-suite leaders within financial services and insurance, drawn from HTEC’s broader global study of 1,529 C-suite executives—including CIOs, CTOs, CDOs, CPOs, CFOs, COOs, CEOs and CSOs—across Saudi Arabia, the UAE, the United Kingdom, the United States, Germany and Spain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215790717/en/ Executive Summary: The State of AI in Financial Services and Insurance 2025 The findings confirm a decisive shift in the industry: not a single respondent said AI is not a priority. L
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom